Abstract Although lymphopenia is currently considered a good predictor for the prognosis of COVID‐19, it must be critically evaluated in patients with CLL, where other clinical markers should be considered to define the prognosis and treatment. Although lymphopenia is currently considered a good predictor for the prognosis of COVID‐19, it must be critically evaluated in patients with CLL, where other clinical markers should be considered to define the prognosis and treatment.
All Keywords
【저자키워드】 SARS‐CoV‐2, Lymphocytic leukemia, CD19+/CD5+ clone, 【초록키워드】 Treatment, Prognosis, COVID‐19, lymphopenia, Patient, CLL, evaluated, to define, clinical marker, 【제목키워드】 Peripheral blood, Patient, Mild, CLL, disease, CD19, clone, Transient,
【저자키워드】 SARS‐CoV‐2, Lymphocytic leukemia, CD19+/CD5+ clone, 【초록키워드】 Treatment, Prognosis, COVID‐19, lymphopenia, Patient, CLL, evaluated, to define, clinical marker, 【제목키워드】 Peripheral blood, Patient, Mild, CLL, disease, CD19, clone, Transient,